Nuclear Translocation of B-Cell-Specific Transcription Factor, BACH2, Modulates ROS Mediated Cytotoxic Responses in Mantle Cell Lymphoma

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Chen, Zheng ^a   Pittman, Eric F ^a   Romaguera, Jorge ^b   Fayad, Luis ^b   Wang, Michael ^b   Neelapu, Sattva S ^b   Mclaughlin, Peter ^b   Kwak, Larry ^b   McCarty, Nami ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; BACH2 PROTEIN; BORTEZOMIB; GLUTATHIONE SYNTHASE; HEME OXYGENASE 1; IDELALISIB; MESSENGER RNA; PROTEIN MCL 1; REACTIVE OXYGEN METABOLITE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; BACH2 GENE; CANCER CELL CULTURE; CAT GENE; CELL NUCLEUS; CELL VIABILITY; CELLULAR DISTRIBUTION; CHEMOSENSITIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOPLASM; DRUG CYTOTOXICITY; DRUG POTENTIATION; EMBRYO; GENE REPRESSION; GSS GENE; HO 1 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTRACELLULAR SIGNALING; MANTLE CELL LYMPHOMA; MCL1 GENE; NRF2 GENE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN TRANSPORT;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASIC-LEUCINE ZIPPER TRANSCRIPTION FACTORS; BLOTTING, WESTERN; BORONIC ACIDS; CELL NUCLEUS; CYTOPLASM; DRUG RESISTANCE, NEOPLASM; HUMANS; LYMPHOMA, MANTLE-CELL; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN TRANSPORT; PYRAZINES; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR CELLS, CULTURED;

EID: 84881010613     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0069126     Document Type: Article

References (41)

1. Leonard JP, Williams ME, Goy A, Grant S, Pfreundschuh M, et al. (2009) Mantle cell lymphoma: biological insights and treatment advances. Clin Lymphoma Myeloma 9: 267-277.
2. Salaverria I, Perez-Galan P, Colomer D, Campo E, (2006) Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica 91: 11-16.
3. Weigert O, Unterhalt M, Hiddemann W, Dreyling M, (2009) Mantle cell lymphoma: state-of-the-art management and future perspective. Leuk Lymphoma 50: 1937-1950.
4. Adams JM, Harris AW, Strasser A, Ogilvy S, Cory S, (1999) Transgenic models of lymphoid neoplasia and development of a pan-hematopoietic vector. Oncogene 18: 5268-5277.
5. Lovec H, Grzeschiczek A, Kowalski MB, Moroy T, (1994) Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J 13: 3487-3495.
6. Cortelazzo S, Ponzoni M, Ferreri AJ, Dreyling M, (2012) Mantle cell lymphoma. Crit Rev Oncol Hematol 82: 78-101.
7. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, et al. (2006) Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24: 4867-4874.
8. Goy A, Younes A, McLaughlin P, Pro B, Romaguera JE, et al. (2005) Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23: 667-675.
9. O'Connor OA, Wright J, Moskowitz C, Muzzy J, MacGregor-Cortelli B, et al. (2005) Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23: 676-684.
10. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, et al. (2007) Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 13: 5291-5294.
11. Adams J, (2001) Proteasome inhibition in cancer: development of PS-341. Semin Oncol 28: 613-619.
12. Rajkumar SV, Richardson PG, Hideshima T, Anderson KC, (2005) Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol 23: 630-639.
13. Perez-Galan P, Roue G, Villamor N, Montserrat E, Campo E, et al. (2006) The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 107: 257-264.
14. Kraus M, Ruckrich T, Reich M, Gogel J, Beck A, et al. (2007) Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells. Leukemia 21: 84-92.
15. Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, et al. (2008) Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112: 2489-2499.
16. Ruckrich T, Kraus M, Gogel J, Beck A, Ovaa H, et al. (2009) Characterization of the ubiquitin-proteasome system in bortezomib-adapted cells. Leukemia 23: 1098-1105.
17. Fribley A, Zeng Q, Wang CY, (2004) Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 24: 9695-9704.
18. Obeng EA, Carlson LM, Gutman DM, Harrington WJ Jr, Lee KP, et al. (2006) Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107: 4907-4916.
19. Weniger MA, Rizzatti EG, Perez-Galan P, Liu D, Wang Q, et al. (2011) Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma. Clin Cancer Res 17: 5101-5112.
20. Ri M, Iida S, Nakashima T, Miyazaki H, Mori F, et al. (2010) Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress. Leukemia 24: 1506-1512.
21. Hoshino H, Kobayashi A, Yoshida M, Kudo N, Oyake T, et al. (2000) Oxidative stress abolishes leptomycin B-sensitive nuclear export of transcription repressor Bach2 that counteracts activation of Maf recognition element. J Biol Chem 275: 15370-15376.
22. Muto A, Hoshino H, Madisen L, Yanai N, Obinata M, et al. (1998) Identification of Bach2 as a B-cell-specific partner for small maf proteins that negatively regulate the immunoglobulin heavy chain gene 3' enhancer. EMBO J 17: 5734-5743.
23. Kamio T, Toki T, Kanezaki R, Sasaki S, Tandai S, et al. (2003) B-cell-specific transcription factor BACH2 modifies the cytotoxic effects of anticancer drugs. Blood 102: 3317-3322.
24. Sakane-Ishikawa E, Nakatsuka S, Tomita Y, Fujita S, Nakamichi I, et al. (2005) Prognostic significance of BACH2 expression in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group. J Clin Oncol 23: 8012-8017.
25. Jung HJ, Chen Z, Fayad L, Wang M, Romaguera J, et al. (2012) Bortezomib-resistant nuclear factor kappaB expression in stem-like cells in mantle cell lymphoma. Exp Hematol 40: 107-118 e102.
26. Jung HJ, Chen Z, McCarty N, (2011) Stem-like tumor cells confer drug resistant properties to mantle cell lymphoma. Leuk Lymphoma 52: 1066-1079.
27. Chen Z, Romaguera J, Wang M, Fayad L, Kwak LW, et al. (2012) Verapamil synergistically enhances cytotoxicity of bortezomib in mantle cell lymphoma via induction of reactive oxygen species production. Br J Haematol 159: 243-246.
28. Leischner U, Schierloh A, Zieglgansberger W, Dodt HU, (2010) Formalin-induced fluorescence reveals cell shape and morphology in biological tissue samples. PLoS One 5: e10391.
29. Chou TC, Talalay P, (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55.
30. Chou TC, Talalay P, (1981) Generalized equations for the analysis of inhibitions of Michaelis-Menten and higher-order kinetic systems with two or more mutually exclusive and nonexclusive inhibitors. Eur J Biochem 115: 207-216.
31. Chou TC, (1976) Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands. J Theor Biol 59: 253-276.
32. Premkumar DR, Jane EP, Agostino NR, Didomenico JD, Pollack IF (2011) Bortezomib-induced sensitization of malignant human glioma cells to vorinostat-induced apoptosis depends on reactive oxygen species production, mitochondrial dysfunction, Noxa upregulation, Mcl-1 cleavage, and DNA damage. Mol Carcinog.
33. Kensler TW, Wakabayashi N, Biswal S, (2007) Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47: 89-116.
34. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, et al. (2009) Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 458: 780-783.
35. Yoshida C, Yoshida F, Sears DE, Hart SM, Ikebe D, et al. (2007) Bcr-Abl signaling through the PI-3/S6 kinase pathway inhibits nuclear translocation of the transcription factor Bach2, which represses the antiapoptotic factor heme oxygenase-1. Blood 109: 1211-1219.
36. Hideshima T, Ikeda H, Chauhan D, Okawa Y, Raje N, et al. (2009) Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 114: 1046-1052.
37. Markovina S, Callander NS, O'Connor SL, Kim J, Werndli JE, et al. (2008) Bortezomib-resistant nuclear factor-kappaB activity in multiple myeloma cells. Mol Cancer Res 6: 1356-1364.
38. Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S, (2008) Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer 7: 40.
39. Perez-Galan P, Mora-Jensen H, Weniger MA, Shaffer AL 3rd, Rizzatti EG, et al (2011) Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood 117: 542-552.
40. Tashiro S, Muto A, Tanimoto K, Tsuchiya H, Suzuki H, et al. (2004) Repression of PML nuclear body-associated transcription by oxidative stress-activated Bach2. Mol Cell Biol 24: 3473-3484.
41. Cremer T, Cremer C, (2001) Chromosome territories, nuclear architecture and gene regulation in mammalian cells. Nat Rev Genet 2: 292-301.